This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
IFITM2 / Interferon-induced transmembrane protein 2 · IHC design guide
Design Immunohistochemistry for IFITM2
Use high staining in bone marrow hematopoietic cells and undetected staining in adipocytes as IHC reference points (HPA tissue IHC). Expect cytoplasmic staining, but interpret it cautiously because antibody staining and RNA expression show low consistency (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
IFITM2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining in several tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A04964-2) | |
| Positive control | Bone marrow+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific) | |
| Caveat | Antibody may detect more than one gene product (HPA tissue IHC) | |
| Regulation | Interferon inducible (UniProt) | |
| Isoform / epitope | No annotated isoforms; cytoplasmic and extracellular regions (UniProt) |
Section 1
Recommended IFITM2 IHC & IF Protocols
The catalog antibody protocol is paired with the published IFITM2 IHC setup for breast tissue and carcinoma specimens (PMC11673214).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A04964-2) |
| Fixation | Image fixative and duration unreported (datasheet A04964-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A04964-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A04964-2) |
| Primary antibody | Rabbit anti-IFITM2, 1:50 recommended; image 1:100 (datasheet A04964-2) |
| Primary incubation | Overnight at 4 °C (datasheet A04964-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A04964-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | IFITM2-positive staining in hematopoietic cells of bone marrow (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 (datasheet A04964-2); the published excerpt does not specify retrieval conditions (PMC11673214).
Section 2
What Is the Expected IFITM2 Staining Pattern?
In paraffin-section IHC, expect chiefly cytoplasmic staining in selected cells, including bone-marrow hematopoietic cells, endometrial stromal cells, and kidney glomerular cells (HPA: high in these cells; cytoplasmic expression in several tissues). Membrane-associated staining is biologically plausible because IFITM2 occupies cell, late-endosome, and lysosome membranes and has one transmembrane segment (UniProt Q01629 topology/localization). Treat the pattern as provisional: HPA rates tissue IHC Uncertain, citing poor agreement with RNA and possible recognition of more than one gene (HPA: tissue IHC reliability).
| Granular or rim-like cytoplasmic signal in hematopoietic cells of bone marrow, with limited nuclear signal. | Consistent with HPA's high staining in those cells and its broad cytoplasmic tissue profile (HPA: bone marrow; tissue profile). Membrane-associated compartments are plausible (UniProt Q01629 localization), but chromogenic IHC alone cannot identify individual endosomes or lysosomes (general IHC practice). Judge the cell-specific pattern alongside controls because tissue IHC reliability is uncertain (HPA: reliability). |
| Predominant, crisp nuclear staining in a paraffin section while the expected cytoplasmic pattern is absent. | This does not match HPA's reported tissue IHC profile (HPA: cytoplasmic expression). Review controls and antibody specificity before assigning it to IFITM2. HPA reports an additional nucleoplasmic ICC-IF location with uncertain status, so a nuclear observation alone cannot establish a genuine tissue IHC pattern (HPA: subcellular ICC-IF). |
| Strong staining of adipocytes, despite little signal in nearby expected-positive cells. | HPA reports IFITM2 as not detected in adipocytes, making this pattern unexpected for that cell type (HPA: adipose tissue). Consider cross-reactivity or endogenous chromogen activity and inspect negative controls (general IHC practice). The HPA tissue result is an uncertain reference pattern, not proof that every adipocyte must be negative (HPA: reliability). |
| Brown signal spread across tissue, lumen, and slide background without a clear cellular pattern. | Treat the distribution as background until control slides show otherwise (general IHC practice). It does not resemble the reported cell-specific cytoplasmic staining (HPA: tissue IHC profile). Review blocking, washing, detection background, and tissue pigment with suitable controls (general IHC practice); do not infer IFITM2 abundance from a uniform deposit. |
| No staining in bone-marrow hematopoietic cells on a run intended to demonstrate a positive control. | HPA reports high staining in these cells, so a blank control warrants a run-level check (HPA: bone marrow). Verify tissue identity, retrieval and detection performance, then assess the catalog antibody against a second validated reagent or orthogonal evidence when available (general IHC practice). HPA's uncertain reliability limits how decisively one negative slide can be interpreted (HPA: reliability). |
💡Expected IFITM2 appearanceCall a section positive when the expected cell population shows distinct cytoplasmic, possibly membrane-associated staining—often strong in HPA-listed high groups such as bone-marrow hematopoietic cells—while diffuse deposition or staining confined to an unexpected cell population calls for control review (HPA: tissue profile and high groups; UniProt Q01629 localization; general IHC practice).
| Membrane topology | IFITM2 has a transmembrane segment at residues 107–127 and cytoplasmic regions at 1–56 and 78–106 (UniProt Q01629 topology). These positions inform interpretation of a known epitope, but the supplied record gives no catalog-antibody epitope; do not predict retrieval needs from topology alone. |
| Tissue and cell selection | HPA reports high staining in endometrial stromal cells and kidney glomerular cells, medium staining in skin fibroblasts, and no detection in adipocytes (HPA: tissue IHC). Choose a documented positive cell population for run assessment and compare the named cell type, not merely the tissue label (general IHC practice). |
| Strength of the IHC reference | The tissue profile has Uncertain reliability because antibody staining agrees poorly with RNA and may include protein from more than one gene (HPA: reliability description). A matching pattern supports an interpretation, but specificity still needs appropriate controls or independent confirmation (general IHC practice). |
| ICC-IF versus tissue IHC | HPA's ICC-IF summary places IFITM2 mainly at cell junctions with an additional uncertain nucleoplasmic location; the tissue IHC summary describes cytoplasmic expression (HPA: subcellular ICC-IF; tissue IHC). Keep these assay-specific observations distinct when assessing a chromogenic paraffin section. |
| Endogenous detection activity | Endogenous enzyme activity or tissue pigment can resemble chromogenic signal, so use detection and negative controls to locate non-antibody color (general IHC practice). No supplied HPA or UniProt evidence assigns a particular endogenous activity to IFITM2-positive cells. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected-positive cells are blank across the whole section. | A failed retrieval or detection step, an inactive primary, or an unsuitable section can erase the run's usable signal (general IHC practice); HPA reports high staining in bone-marrow hematopoietic cells (HPA: bone marrow). | Check a positive-control section and reagent controls, confirm the selected cells are present, and review the catalog antibody's IHC-P instructions before changing conditions (general IHC practice). |
| Signal is weak in an HPA-listed high cell population. | The run may have low analytical sensitivity, or the reference pattern may not reproduce with this antibody; HPA rates tissue IHC Uncertain (HPA: reliability). | Compare a same-run positive control, inspect detection and retrieval records, and score localization separately from intensity (general IHC practice). Avoid calling a weak signal definitively negative. |
| Unexpected cells stain strongly while the documented cell population does not. | Cross-reactivity or nonspecific detection is possible (general IHC practice); HPA warns that tissue staining may include protein from more than one gene (HPA: reliability description). | Identify the stained cell type, compare the relevant HPA cell-level entry, and seek an independent antibody or orthogonal result before assigning IFITM2 (HPA: tissue IHC; general IHC practice). |
| A diffuse brown haze obscures cellular boundaries. | Nonspecific reagent binding, incomplete washing, or detection background can produce haze (general IHC practice). HPA describes a cytoplasmic tissue pattern rather than a featureless field (HPA: tissue profile). | Review negative and detection-only controls, then optimize blocking, washing, and chromogen exposure within the validated IHC workflow (general IHC practice). |
| Signal looks exclusively nuclear. | The result conflicts with the HPA cytoplasmic tissue IHC profile; HPA's nucleoplasmic ICC-IF annotation is uncertain and comes from a different assay (HPA: tissue IHC; subcellular ICC-IF). | Check the counterstain and negative controls, then confirm with an independent reagent before scoring nuclear staining as IFITM2 (general IHC practice). |
| IF/ICC Q&A: should cell-junction fluorescence dictate the paraffin IHC score? | HPA reports approved cell-junction localization in ICC-IF, whereas its tissue IHC profile is cytoplasmic (HPA: subcellular ICC-IF; tissue IHC). The observations come from different assay contexts. | Score the paraffin section against its tissue-specific IHC cell and compartment pattern, and consult the separate IF/ICC guide for fluorescence interpretation (HPA: tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing IFITM2 staining
A04964-2 · IHCIHC analysis of IFITM2 using anti-IFITM2 antibody (A04964-2). IFITM2 was detected in a paraffin-embedded section of human breast cancer tiss
A04964-2 · IHCIHC analysis of IFITM2 using anti-IFITM2 antibody (A04964-2). IFITM2 was detected in a paraffin-embedded section of human lung cancer tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000185201-IFITM2/tissue/cerebral+cortex#imid_1600772
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000185201-IFITM2/tissue/colon#imid_1600690
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000185201-IFITM2/tissue/liver#imid_1600699
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000185201-IFITM2/tissue/kidney#imid_1600700
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA044731; green = IFITM2, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA044731; green = IFITM2, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for IFITM2 IHC & IF
🧪Run bone marrow first; hematopoietic cells should stain (HPA: High in hematopoietic cells). Use adipose tissue as the negative comparator, where adipocytes are not detected (HPA: Not detected in adipocytes); on the bone marrow slide, assess unstained cells against the no-primary control as internal background without assigning an unsupported negative cell type.
Positive control tissue: Bone marrow (Hematopoietic cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show IFITM2 in A-431, U2OS, with annotated localisation: Cell Junctions (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) slide, a concentration-matched rabbit IgG isotype control, and IFITM2 knockout material as a biological negative (caption: rabbit primary antibody; standard IHC controls). Quench endogenous peroxidase before chromogenic detection, particularly in hematopoietic cells (HPA: High in bone marrow hematopoietic cells; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected A04964-2 paraffin-section caption does not state a fixative (selected tissue-IHC caption). That caption uses heat retrieval in EDTA at pH 8.0 and a 1:100 primary dilution, providing an IHC starting point without establishing that retrieval is required for bone marrow (selected tissue-IHC caption). Whether frozen sections or IF are easier is unreported; bone marrow endogenous peroxidase can complicate chromogenic interpretation (HPA: High in bone marrow hematopoietic cells; standard IHC practice).
HPA tissue IHC evidence for IFITM2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | High | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | High | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | High | Protein (IHC) | HPA → |
| Kidney | Cells in glomeruli | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced IFITM2 IHC Tips
Troubleshoot IFITM2 staining in paraffin sections by checking retrieval, compartment, cell identity, and controls before comparing signal across samples.
Which retrieval conditions should I start with for IFITM2 IHC?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A04964-2). The selected tissue caption used those conditions before overnight primary incubation at 4°C, but gives no heating duration or temperature; record both when optimizing your run (datasheet A04964-2; standard IHC practice). If signal is weak, vary heating duration on matched sections while holding antibody dilution, detection, and development constant (standard IHC practice). Compare cellular distribution as well as intensity: IFITM2 is annotated at cell, late endosome, and lysosome membranes, while tissue IHC has shown broader cytoplasmic staining with uncertain reliability (UniProt Q01629 localisation; HPA: tissue IHC, Uncertain).
Could fixation explain weak or uneven IFITM2 staining?
Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not state a fixative, and neither tissue staining patterns nor protein topology establish a fixation effect (datasheet A04964-2; HPA: tissue IHC; UniProt Q01629 topology). For IHC troubleshooting, compare sections processed with documented fixation and processing histories, keeping retrieval and antibody incubation identical (standard IHC practice). Examine whether weak staining tracks with section thickness, tissue preservation, or delayed processing before changing antibody concentration (standard IHC practice). Include a concurrently processed positive control, such as marrow hematopoietic cells, while treating its reported high staining as provisional because HPA rates tissue IHC reliability uncertain (HPA: High in bone marrow hematopoietic cells; HPA: Uncertain).
How should membrane and cytoplasmic IFITM2 staining be assessed?
Assess the distribution within identifiable cells rather than requiring a crisp plasma-membrane rim: IFITM2 is annotated at the cell, late endosome, and lysosome membranes, and HPA describes cytoplasmic tissue staining (UniProt Q01629 localisation; HPA: tissue IHC profile). Its annotated transmembrane segment spans residues 107–127, with cytoplasmic regions at 1–56 and 78–106 (UniProt Q01629 topology). Compare similar cell populations on the same slide before interpreting a diffuse DAB haze as intracellular signal (standard IHC practice). Junctional staining has support from HPA subcellular imaging, whereas its additional nucleoplasmic assignment is uncertain; nuclear-only DAB staining therefore warrants control review (HPA: cell junctions approved; nucleoplasm uncertain).
What epitope issues matter when IFITM2 staining looks inconsistent?
Check the catalog antibody’s stated immunogen or epitope before attributing a staining difference to IFITM2 biology; the supplied tissue caption does not identify that epitope (datasheet A04964-2). UniProt lists no annotated isoforms and places cytoplasmic regions at 1–56 and 78–106, followed by a transmembrane segment at 107–127 and a short extracellular region at 128–132 (UniProt Q01629 topology and isoforms). The record also notes N-acetylmethionine at residue 1 and phosphotyrosine at 19, without establishing effects on this antibody (UniProt Q01629 modified residues). Use matched positive and negative controls to investigate cross-reactivity, especially because HPA cautions that its tissue antibody targets protein from more than one gene (HPA: tissue IHC reliability description).
How can IF help resolve ambiguous IFITM2 IHC staining?
Use IF as an independent localisation check, pairing IFITM2 with a marker for the cell population under study; a hematopoietic lineage marker is relevant when examining marrow cells reported as high by HPA (HPA: High in bone marrow hematopoietic cells; standard IF practice). Select fluorophores after checking unstained tissue for autofluorescence, and acquire single-label controls before interpreting overlap (standard IF practice). If the antibody epitope is cytoplasmic, include a controlled permeabilisation step to expose it; confirm the epitope first because the supplied caption does not specify one (UniProt Q01629 topology; datasheet A04964-2; standard IF practice). HPA reports junctional localisation in cell imaging, but its nucleoplasmic assignment is uncertain, so compare IF patterns with compartment markers rather than assuming nuclear signal is specific (HPA: cell junctions approved; nucleoplasm uncertain).
What should I adjust when DAB background obscures IFITM2?
First inspect a no-primary control to separate detection-system staining from primary-antibody staining (standard IHC practice). For the selected paraffin-section example, the primary was used at 1:100 overnight at 4°C after a 10% goat-serum block, with peroxidase-linked detection and DAB (datasheet A04964-2). If background remains, verify the peroxidase block, shorten DAB development, and compare a more dilute primary on adjacent sections while preserving the same retrieval conditions (standard IHC practice). Judge improvement in defined cells against the no-primary slide, since HPA reports cytoplasmic expression across several tissues and rates its tissue staining reliability uncertain (HPA: tissue IHC profile; HPA: Uncertain).
How should IFITM2 IHC be scored across samples? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, because IFITM2 has cell, late endosome, and lysosome membrane annotations while tissue IHC is described as cytoplasmic (UniProt Q01629 localisation; HPA: tissue IHC profile). For comparable sections, report the percentage of positive target cells and an H-score based on staining intensity and percentage, using one threshold and review procedure throughout (standard IHC practice). If cell abundance varies, also report positive-cell density per mm² of viable tissue and normalise comparisons to the number of evaluable cells or viable area (standard IHC practice). Exclude folds and necrotic regions consistently, and qualify any cross-sample biological claim because HPA rates its tissue IHC evidence uncertain (standard IHC practice; HPA: Uncertain).
When is an apparent IFITM2-positive result credible?
Treat staining as more credible when it follows identifiable cell boundaries or intracellular compartments and persists in replicate sections, consistent with IFITM2 membrane annotations and HPA’s cytoplasmic tissue profile (UniProt Q01629 localisation; HPA: tissue IHC profile; standard IHC practice). Check cell identity: HPA reports high staining in marrow hematopoietic cells and stromal cells of endometrium, but its tissue IHC reliability is uncertain (HPA: High in bone marrow hematopoietic cells and endometrial stroma; HPA: Uncertain). Nuclear-only signal needs caution because HPA labels nucleoplasmic localisation uncertain (HPA: nucleoplasm uncertain). Reject interpretations driven by section-edge staining, necrosis, or signal reproduced in a no-primary control; inspect the peroxidase block when endogenous enzyme activity is suspected (standard IHC practice).
Boster reagents
Best IFITM2 / Interferon-induced transmembrane protein 2 IHC Antibodies
A04964-2 has IHC images from human breast and lung cancer paraffin sections (catalog image captions). IF and ICC are listed applications, but no IF image is supplied (catalog applications; image payload).
Real IHC data
Anti-IFITM2 Antibody
Cat # A04964-2
A04964-2 will render with its IHC figure from a human breast cancer paraffin section (card image caption). Its catalog also shows IHC on a human lung cancer paraffin section and lists IF and ICC applications for human samples (catalog image caption; applications; reactivity).
Which to pick: Choose A04964-2 for paraffin-section IHC: its own captions document heat retrieval in EDTA at pH 8.0, while the fixative is unreported (catalog image captions). The same rabbit polyclonal antibody is listed for IF/ICC, although no IF image is supplied (catalog host; dilution record; applications; image payload). Cross-species use is unsupported because the catalog lists only human reactivity (catalog reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q01629 (IFM2_HUMAN, Interferon-induced transmembrane protein 2).
- Human Protein Atlas. IFITM2 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. IFITM2 subcellular location (ICC-IF): Mainly localized to the cell junctions. In addition localized to the nucleoplasm..
- Human Protein Atlas. IFITM2 antibody validation summary (2 antibodies).
- Widespread but tissue-specific patterns of interferon-induced transmembrane protein 3 (IFITM3, FRAGILIS, MIL-1) in the mouse gastrula. Gene expression patterns : GEP 2013 — PMC3704145.
- Genes Associated with the Immune System Affected by Ionizing Radiation and Estrogen in an Experimental Breast Cancer Model. Biology 2024 — PMC11673214.
- Interferon-induced transmembrane protein 2 is a prognostic marker in colorectal cancer and promotes its progression by activating the PI3K/AKT pathway. Discover oncology 2024 — PMC11130111.
- BAG3(+) CAF-T cell neighborhood predicts resistance to neoadjuvant chemoimmunotherapy in NSCLC. Frontiers in immunology 2026 — PMC13385752.
- PubMed PMID:1906403 — UniProt-cited evidence.
- PubMed PMID:16554811 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for IFITM2 (Interferon-induced transmembrane protein 2). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A04964-2). Validated IHC antibody: A04964-2 at 1:50 recommended; image 1:100 (the product's own IHC validation image is shown). Controls (HPA): positive Bone marrow (Hematopoietic cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A04964-2); 2. Fixation: Image fixative and duration unreported (datasheet A04964-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A04964-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A04964-2); 8. Primary antibody: Rabbit anti-IFITM2, 1:50 recommended; image 1:100 (datasheet A04964-2); 9. Primary incubation: Overnight at 4 °C (datasheet A04964-2). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Caveat: Antibody may detect more than one gene product (HPA tissue IHC); Isoform / epitope: No annotated isoforms; cytoplasmic and extracellular regions (UniProt); Regulation: Interferon inducible (UniProt). Evidence: UniProt Q01629, HPA tissue IHC · Uncertain, HPA ICC-IF · Mainly localized to the cell junctions. In addition localized to the…, Datasheet A04964-2, PMC11673214. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/IFITM2/immunohistochemistry-ihc-guide.